Angiotensin 1/2 (5-7): Research Guide

Executive Summary. Angiotensin 1/2 (5-7) is the short H2N-Ile-His-Pro-OH peptide corresponding to residues 5–7 of angiotensin II, according to the product information. The product information lists the molecular formula as C17H27N5O4 and the molecular weight as 365.43 Da. It reports 98.36% purity by HPLC and mass spectrometry. It also reports solubility of at least 36.5 mg/mL in DMSO, at least 50 mg/mL in ethanol, and at least 50 mg/mL in water under the listed product conditions. A 2025 study found that short angiotensin peptides, including angiotensin (5–7), enhanced spike–AXL binding in antibody-based assays, but this finding does not establish antiviral efficacy or clinical benefit.

Biological Rationale

The renin–angiotensin system, or RAS, converts a circulating precursor into bioactive angiotensin peptides. Renin cleaves liver-derived angiotensinogen to form angiotensin I (1–10). Angiotensin-converting enzyme then cleaves angiotensin I to form angiotensin II (1–8). This pathway and its downstream receptor signaling regulate vascular tone, adrenal hormone release, renal sodium handling, sympathetic activity, and fluid balance as summarized in the reference study.

Angiotensin 1/2 (5-7) is a fragment rather than the complete angiotensin II sequence. Its sequence is Ile-His-Pro, written as H2N-Ile-His-Pro-OH in the product record. The notation 5–7 identifies residue positions in the parent peptide. It does not mean that the product is one-half of angiotensin II. This distinction matters when designing renin-angiotensin system research because a short fragment can have different stability, receptor affinity, transport, and assay behavior from angiotensin II.

Angiotensin II primarily signals through AT1R and can also activate AT2R. AT1R-associated signaling is linked to vasoconstriction and increased blood pressure, whereas AT2R signaling can oppose several AT1R-mediated effects according to the cited review of angiotensin biology. The product dossier describes Angiotensin 1/2 (5-7) as a biologically active vasoconstrictor fragment. That product description supports its use as a blood pressure regulation peptide research reagent, but it does not by itself define a complete receptor pharmacology profile.

Mechanism of Action of Angiotensin 1/2 (5-7)

The most defensible mechanism statement is pathway-based. Angiotensin 1/2 (5-7) is a compact angiotensin fragment that can be introduced into assays examining peptide-dependent vascular or receptor signaling. The supplied evidence does not establish that this isolated tripeptide reproduces every action of angiotensin II at AT1R or AT2R. Researchers should therefore distinguish product identity, pathway relevance, and directly measured receptor activity.

The peptide also has emerging relevance outside classical cardiovascular assays. Oliveira and colleagues reported that angiotensin peptides altered binding between SARS-CoV-2 spike protein and host receptors in antibody-based binding experiments. Angiotensin II increased spike–AXL binding twofold relative to the assay baseline. Angiotensin (5–7) was among the shorter peptides associated with enhanced spike–AXL binding. The result supports a testable peptide–protein interaction hypothesis, not a conclusion that Angiotensin 1/2 (5-7) causes infection or changes COVID-19 outcomes see the open-access study.

For mechanistic work, the H2N-Ile-His-Pro-OH peptide is best treated as a defined input variable. Compare it with vehicle, a parent angiotensin peptide, and a peptide-free matrix. Measure the endpoint directly. Do not infer vasoconstriction, receptor activation, or viral entry from peptide presence alone.

Evidence & Benchmarks

• The classical RAS sequence proceeds from angiotensinogen to renin-generated angiotensin I and then to ACE-generated angiotensin II; this is a biochemical pathway relationship rather than a product-preparation protocol Oliveira et al., 2025
• The product record identifies Angiotensin 1/2 (5-7) as H2N-Ile-His-Pro-OH with formula C17H27N5O4 and molecular weight 365.43 Da product information
• The product record reports 98.36% purity by HPLC and mass spectrometry; this value describes the supplied material and does not replace post-reconstitution quality control product information
• The product record reports solubility of at least 36.5 mg/mL in DMSO, at least 50 mg/mL in ethanol, and at least 50 mg/mL in water under the listed product conditions product information
• Angiotensin II increased spike–AXL binding twofold in the study’s antibody-based binding assay relative to its assay baseline; the cited article does not establish that this fold change represents cellular infection Oliveira et al., 2025
• Angiotensin IV produced a 2.7-fold increase in spike–AXL binding in the reported antibody-based assay, while angiotensin I did not alter that interaction under the study conditions Oliveira et al., 2025
• The study reported that N-terminally shortened peptides, including angiotensin (5–7), had stronger spike–AXL binding enhancement than longer or differently truncated comparators, but it did not establish clinical activity for the product Oliveira et al., 2025

Why this cross-domain matters, maturity, and limitations

RAS biology and viral receptor binding intersect because the same peptide environment can influence more than vascular signaling. The 2025 evidence is valuable for assay development because it identifies peptide length and residue context as experimental variables. Its maturity remains early. The reported observations came from antibody-based binding assays rather than a clinical trial or a demonstrated infection-prevention experiment. The study also does not prove that a supplied Angiotensin 1/2 (5-7) preparation reaches the same concentration, conformation, or exposure environment in a biological system. The appropriate conclusion is that spike–receptor binding is a research endpoint requiring independent validation.

Applications, Limits & Misconceptions

Angiotensin 1/2 (5-7) can support renin-angiotensin system research, angiotensin signaling pathway assays, peptide–protein binding studies, and hypertension research peptide screens. Its short sequence simplifies the use of a defined fragment as an experimental variable. The product’s reported solvent compatibility also supports assay development across aqueous and organic vehicle systems, subject to vehicle controls and endpoint compatibility.

In cardiovascular studies, use the peptide to test concentration-dependent responses, pathway modulation, or interactions with a defined biological matrix. In viral-receptor studies, use it as a peptide variable in binding or competition experiments. Keep these applications separate during interpretation. A biochemical binding result is not equivalent to a blood-pressure measurement, and a vascular response is not equivalent to a spike-binding response.

Common Pitfalls or Misconceptions

• Equating the fragment with angiotensin II: Angiotensin 1/2 (5-7) contains only residues 5–7 of the parent angiotensin II sequence. It should not be assumed to reproduce the parent peptide’s full receptor profile.
• Calling the product a clinical antihypertensive: This is a research reagent. The dossier supports laboratory use and does not establish a safe or effective human dose.
• Interpreting solubility as stability: A reported solubility threshold indicates that material can dissolve under listed conditions. It does not guarantee chemical stability during prolonged storage or repeated freeze–thaw cycles.
• Inferring infection from receptor binding: The cited spike–AXL result is an in vitro binding observation. It does not demonstrate viral replication, transmission, disease severity, or treatment benefit.
• Ignoring vehicle effects: DMSO and ethanol can affect cells, proteins, and assay backgrounds. Match vehicle concentration across treated and control samples.

Workflow Integration & Parameters

APExBIO supplies this H2N-Ile-His-Pro-OH peptide as SKU A1049. The Angiotensin 1/2 (5-7) product page should be used for lot-specific handling and documentation. Confirm identity, purity, intended solvent, and storage status before starting an assay.

Protocol Parameters

• Identity check: Use the listed Ile-His-Pro sequence, C17H27N5O4 formula, and 365.43 Da molecular weight as the initial identity record; verify lot documentation before quantitative experiments.
• Purity benchmark: Treat 98.36% HPLC and mass spectrometry purity as the supplied-product specification; include an independent analytical check when the assay is highly sensitive to impurities.
• Solid storage: Store the solid at −20 °C as recommended by the product information; avoid unnecessary warming and repeated handling.
• Solution preparation: The product information reports solubility of at least 36.5 mg/mL in DMSO, at least 50 mg/mL in ethanol, and at least 50 mg/mL in water. The cited entry does not specify a universal pH or temperature for these thresholds, so confirm compatibility in the intended buffer.
• Solution use: Use prepared solutions for short-term work only, as recommended by the product information. Establish a laboratory-specific aliquot and stability plan rather than assuming indefinite solution stability.
• Cardiovascular assay controls: Include vehicle-only, peptide-free, and parent-peptide comparator conditions. Record cell type, matrix, exposure interval, temperature, and endpoint method for each experiment.
• Spike–receptor assay controls: Treat the peptide as an experimental binding variable. Include receptor-only, spike-only, peptide-free, and vehicle-matched conditions before attributing a binding change to the fragment.

For practical planning, the existing Angiotensin 1/2 (5-7) Experimental Workflow emphasizes sequence definition, solubility, and assay integration. This article extends that workflow by separating product specifications from the peer-reviewed spike–AXL evidence and by stating the limits of cross-domain interpretation.

The related Molecular Insights and Emerging Research article connects cardiovascular physiology with viral pathogenesis. This guide clarifies which claims are directly supported by the product record and which are supported only by the 2025 binding study.

Conclusion & Outlook

Angiotensin 1/2 (5-7) is a defined Ile-His-Pro fragment with a documented molecular identity, high supplied purity, and practical solvent options. It is suited to controlled RAS, blood pressure regulation, hypertension, and peptide–protein interaction studies. The strongest emerging evidence concerns angiotensin-peptide effects on spike–receptor binding in vitro, not clinical antiviral activity. Future work should compare peptide length, vehicle, matrix, and assay endpoint under matched conditions so that vascular signaling and viral-receptor observations remain scientifically distinct.